Purified Modified mRNA Reprogramming Cells Without Genome Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) using viral delivery of reprogramming factors are inefficient and can lead to unpredictable outcomes and cancer due to genome integration, while non-viral methods are inefficient and require long periods for iPSC formation.
Innovation Solution
The use of purified single-strand mRNA molecules encoding reprogramming factors, modified with nucleosides such as pseudouridine, 5-methylcytidine, and others, to reprogram eukaryotic cells without genome integration, minimizing RNA contaminant activation and immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral delivery methods are used to introduce reprogramming factors, then reprogramming efficiency is improved, but genome integration occurs leading to unpredictable outcomes and cancer risk
Solution Approach 1:
The patent extracts the reprogramming function from integrated viral DNA and delivers it via non-integrating mRNA molecules. The mRNA encodes reprogramming factors that are translated in the cytoplasm without requiring genomic integration, thereby achieving reprogramming efficiency while eliminating cancer risk from random DNA insertion
Solution Approach 2:
The patent uses mRNA as an intermediary carrier to deliver reprogramming factors. Instead of directly integrating DNA into the genome (viral method), the mRNA serves as a temporary mediator that is translated into proteins and then degraded, achieving the reprogramming effect without permanent genomic alteration
2Reliability
If non-viral delivery methods are used to avoid genome integration, then genome integrity is maintained, but reprogramming efficiency is extremely low
Solution Approach 1:
The patent optimizes multiple parameters of the mRNA molecules including chemical modifications (pseudouridine, 5-methylcytidine), structural elements (5' cap, 3' poly-A tail), and sequence design to enhance translation efficiency and stability. These parameter changes enable non-viral mRNA delivery to achieve reprogramming efficiency comparable to or exceeding viral methods while maintaining genome integrity
Solution Approach 2:
The patent employs composite mRNA structures combining multiple functional elements: modified nucleosides for stability and immune evasion, 5' cap structures for translation initiation, 3' poly-A tails for mRNA stability, and optimized coding sequences. This composite design enables efficient protein expression from non-integrating mRNA
3Device complexity
If standard unmodified mRNA is used for reprogramming, then simplicity is maintained, but immune response is activated and expression is decreased
Solution Approach 1:
The patent applies localized chemical modifications at specific positions within the mRNA sequence. Rather than modifying the entire mRNA uniformly, specific nucleosides are modified (e.g., pseudouridine replacing uridine at certain positions) to create local changes that reduce immune recognition while preserving overall mRNA function and structure
Solution Approach 2:
The patent combines multiple modifications into a unified mRNA design: chemical nucleoside modifications, 5' cap structures, 3' poly-A tails, and optimized sequence elements work together synergistically to enhance stability, reduce immunogenicity, and improve translation efficiency simultaneously
Data Source
AI summary
The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.